KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--CSL Behring (ASX: CSL) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for PrivigenTM (Immune Globulin Intravenous (Human), 10% Liquid), an intravenous immunoglobulin (IVIg) for treating patients diagnosed with primary immunodeficiency (PI). Privigen is also indicated for the treatment of chronic immune thrombocytopenic purpura (ITP) to rapidly raise platelet counts to prevent bleeding.
